Article
Nov 12, 2025

Improving Biological Age with GLP-1 RAs: An Analysis of a Study 

This is a further dive into and expansion of a Journal Club video that I offered in September 2025 in response to a fascinating article related to the power of GLP-1 peptides to create positive epigenetic changes at the cellular level. 

The study, Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial, is in preprint and has not yet been peer-reviewed, but offers substantive evidence of semaglutide’s versatile effects on cellular pathways related to metabolism, inflammation, and the immune system. In particular, the study examines the use of semaglutide (a GLP-1 receptor agonist) to control or slow the epigenetic aging of people with HIV (PWH) and  associated lipohypertrophy, a common condition with this population of patients. 

Through the lens of “the emerging geroscience paradigm” (Kennedy,et al, 2014), the study authors suggest that HIV-associated lipohypertrophy (a condition characterized by excessive accumulation of visceral and ectopic adipose tissue) offers an opportunity to examine the impact of semaglutide on a cohort who represent the “accelerated-aging phenotype” and look at possible implications for GLP-1 RAs as agents that improve biological age.

I was drawn to this article because of its focus on the pleiotropic power of GLP-1 RAs, a topic that I’ve discussed in several Masterminds, focused on in my soon-to-be released weight loss course, and devoted an entire book to – The Quantum Power of GLP-1 Peptides (SSRP, 2025). As we know from the plethora of existing research, GLP-1 peptides such as Semaglutide decrease inflammation, improve metabolism, and support the immune system. The two-part question that the article prompted for me was this: if GLP-1 RAs can positively affect cellular metabolism, immune function, and inflammation, thereby altering the cellular environment, wouldn’t it make sense that they also have the potential to increase the healthspan – or lifespan – of the cell? And I think the answer, intuitively, is – absolutely.  

Members-Only Content

This article contains exclusive content for SSRP members. Join today to unlock the full article and gain access to our entire library of resources.

Unlock Full Article
RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
VIDEO
Cellular Medicine Mondays
May 11, 2026
Ep. 087 - The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation
Preview Only
Journal Club – Episode 087

The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation

Dr. Seeds unpacks how RAS receptor balance drives inflammation, fibrosis, mitochondrial dysfunction, and tissue remodeling, far beyond its classical role in blood pressure regulation. (Article Link)

Preview Only — Become a member for full access
SSRP Institute May 6, 2026
Nutrition Education for Physicians and Medical Students
HEADLINE SCIENCE MAY 6, 2026 —Earlier in March, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Education announced an initiative to emphasize nutrition at the nation’s top medical schools. Reflecting U.S. Health and Human Services Secretary Robert Kennedy’s commitment to preventative medicine, this initiative will require “meaningful nutrition training” […]
READ NEWS
VIDEO
Cellular Medicine Mondays
May 4, 2026
Ep. 086 - May '26
Preview Only
SSRP Institute Apr 29, 2026
New ACC and AHA Cholesterol Management Guidelines
HEADLINE SCIENCE APRIL 29, 2026 – The American College of Cardiology (ACC) and American Heart Association (AHA) have updated their cholesterol management guidelines, advocating for earlier and more aggressive intervention based on the understanding that cumulative lifetime exposure to high LDL-C drives atherosclerotic cardiovascular disease (ASCVD) risk. The guidelines aim to standardize care for dyslipidemia […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Apr 27, 2026
Ep. 085 - Peptide Pharmacokinetics
Preview Only
Dissecting Protocols – Episode 085

Peptide Pharmacokinetics

Dissecting Protocols, Dr. Seeds breaks down the reasoning behind SubQ vs. IM peptide administration. From pharmacokinetic considerations to the growing misuse of combining peptides with oil-based medications in the same syringe, this discussion helps clarify proper application and safety considerations.

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Apr 21, 2026
A Review of Circadian Processes and Evidence-Based Interventions to Improve Sleep
William Seeds, MD Apr 21, 2026
A Review of Circadian Processes and Evidence-Based Interventions to Improve Sleep
Introduction In March of this year, I did a Rabbit Hole (Episode 079) in which I discussed a number of trends marketed to the wider public promising sleep improvement. As you know, a huge swath of the population suffers from sleep disturbance. According to the NIH, approximately 30% to 40% of US adults report sleep […]
READ ARTICLE
VIDEO
Cellular Medicine Mondays
Apr 20, 2026
Ep. 084 - The Cellular Impact of UVA vs. UVB Light (Part 2)
Preview Only
Rabbit Holes – Episode 084

The Cellular Impact of UVA vs. UVB Light (Part 2)

Dr. Seeds continues this Rabbit Hole on UVA vs. UVB light in Part 2, covering oxidative stress, skin aging, vitamin D synthesis, and the risks of tanning beds. A helpful look at why not all UV exposure works the same, why that distinction matters, and how it shapes both skin health and cellular function

Catch Part 1 (Rabbit Holes – Ep. 081) HERE

Preview Only — Become a member for full access
SSRP Institute Apr 15, 2026
FDA Announces Change in Status of 12 Peptides
BREAKING NEWS APRIL 15, 2026 – In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500. Originally nominated for Category 2 (Bulk Substances that […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Apr 13, 2026
Ep. 083 - Safety of Low-Dose Oral Minoxidil for Hair Loss: A Multicenter Study of 1404 Patients
Preview Only
Journal Club – Episode 083

Safety of Low-Dose Oral Minoxidil for Hair Loss: A Multicenter Study of 1404 Patients

Dr. Seeds discusses this article on low dose minoxidil for hair loss and shares why a lower, slower dosing approach may lead to better outcomes. He also reviews key safety considerations, side effects, and practical dosing insights for both men and women. (Article Link)

Preview Only — Become a member for full access
SSRP Institute Apr 9, 2026
SSRP Institute Welcomes StemWave as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [April 9, 2026] — The SSRP Institute announces that StemWave has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. StemWave provides an FDA-listed, non-invasive acoustic wave therapy platform used in musculoskeletal care. The technology delivers focused mechanical energy to targeted tissues, supporting improved circulation, […]
READ NEWS

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.